- The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale Total Score (p ≤0.021 and p ≤0.542, respectively)
- Roluperidone separated from placebo on both primary and key secondary endpoints at Weeks 4, 8 and 12
-
Roluperidone was generally well tolerated with a safety profile comparable to placebo
http://ir.minervaneurosciences.com/news-releases/news-release-details/minerva-neurosciences-announces-results-phase-3-trial
http://ir.minervaneurosciences.com/static-files/215190cc-8124-4040-b6ae-4fb52ea6578c
Too late jamesbond! I beat you to it !
2 Likes